Canakinumab

證據等級: L5

預測適應症: 10 個

Canakinumab: From Autoinflammatory Syndromes to Familial Mediterranean Fever

One-Sentence Summary

Canakinumab is a human anti-IL-1β monoclonal antibody whose established use is in IL-1β–driven autoinflammatory diseases such as Cryopyrin-Associated Periodic Syndromes (CAPS). TxGNN generated 10 candidate indications for this drug; most (7 of 10) turn out to be low-confidence or entity-mismatched signals, but Familial Mediterranean Fever (FMF) stands out with 7 clinical trials (5 completed Phase 3) and 20 publications, and is already an approved indication for canakinumab in other jurisdictions (FDA/EMA) — while the product remains unmarketed locally (0 authorizations).

Quick Overview

Item	Content
Original Indication	Autoinflammatory disease (Cryopyrin-Associated Periodic Syndromes / CAPS family) — no local approved-label text available; drawn from literature evidence (PMID 20065636)
Predicted New Indication	Familial Mediterranean Fever (autosomal dominant)
TxGNN Prediction Score	99.41%
Evidence Level	L1
Finland Market Status	✗ Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Canakinumab is a fully human monoclonal antibody that binds and neutralizes interleukin-1β (IL-1β), the central cytokine driving inflammasome-mediated autoinflammatory disease (per literature evidence PMID 20065636, PMID 35874710). Its established efficacy is in the CAPS spectrum (FCAS, Muckle-Wells syndrome, NOMID/CINCA), where uncontrolled NLRP3-inflammasome activity leads to IL-1β overproduction.

FMF shares the same downstream biology: gain-of-function MEFV mutations dysregulate the pyrin inflammasome, driving IL-1β overactivation and recurrent fever/serositis attacks. Because canakinumab's mechanism acts directly downstream of this shared IL-1β pathway, its extension from CAPS to FMF is mechanistically coherent rather than speculative — and in fact canakinumab already carries FMF as an approved indication in other jurisdictions, per the evidence pack's own rationale ("已獲多國（含 FDA/EMA）核准之適應症，非單純 TxGNN 預測").

One caveat worth flagging: most of the pivotal trials captured under this candidate's evidence set are titled as CAPS/TRAPS/Muckle-Wells studies rather than FMF-specific studies. This likely reflects that these are the drug's foundational registrational trials for the broader hereditary periodic fever syndrome label (which was later extended to include FMF), rather than FMF being untested — the one explicitly FMF-inclusive study (NCT06838143, real-world REASSURE) is ongoing. This should be verified against the actual approved label text before final sign-off.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00465985	Phase 3	Completed	35	Pivotal 3-part randomized, double-blind, placebo-controlled withdrawal trial establishing efficacy/safety of canakinumab in Muckle-Wells syndrome (CAPS)
NCT00685373	Phase 3	Completed	166	Largest long-term (≥6 month) open-label safety/efficacy cohort across CAPS phenotypes (FCAS, MWS, NOMID)
NCT00991146	Phase 3	Completed	19	6-month open-label efficacy/safety study in Japanese CAPS patients, extended pending Japan approval
NCT01302860	Phase 3	Completed	17	One-year open-label multicenter trial assessing efficacy, safety and tolerability in patients ≤4 years, including childhood vaccination safety
NCT01576367	Phase 3	Completed	17	Open-label extension providing long-term efficacy/safety/tolerability data in CAPS patients
NCT01242813	Phase 2	Completed	20	4-month multicenter dose-finding study of canakinumab in active recurrent/chronic TRAPS
NCT06838143	N/A	Recruiting	25	Real-world non-interventional safety/effectiveness study (REASSURE) explicitly covering colchicine-resistant FMF (crFMF), CAPS, TRAPS, HIDS/MKD, sJIA; ongoing through 2028

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35874710	2022	Systematic Review	Frontiers in Immunology	Systematic review of safety/efficacy of IL-1-targeted biologics (anakinra, canakinumab, rilonacept) across immune-mediated autoinflammatory disorders
37769252	2024	Systematic Review / Meta-analysis	Rheumatology (Oxford)	Efficacy and safety of anti-IL-1 treatment specifically in FMF patients unresponsive/intolerant to colchicine
29768139	2018	Review	New England Journal of Medicine	Canakinumab evaluated across monogenic autoinflammatory recurrent fever syndromes including FMF, MKD/HIDS and TRAPS
40040547	2025	Cohort	Int J Rheum Dis	Compares attack characteristics, acute-phase reactants and renal outcomes in FMF patients on canakinumab with/without colchicine
32806879	2020	Review	Turkish J Med Sci	Contemporary review of FMF pathogenesis through treatment, including biologic options
30686512	2019	Review	Presse Médicale	Overview of FMF epidemiology, MEFV/pyrin pathophysiology and treatment
28362189	2017	Review	Expert Rev Clin Immunol	Focused review of canakinumab specifically for FMF treatment
36062765	2022	Review	Clin Exp Rheumatol	IL-1 inhibition in FMF: clinical outcomes and expectations
31205631	2019	Review	Mediterr J Hematol Infect Dis	FMF clinical impact and treatment plan formulation
34684086	2021	Review	Medicina (Kaunas)	Amyloidosis and glomerular disease as FMF complications, relevant to treatment goals

Other TxGNN-Predicted Indications (Screened, Not Pursued)

For transparency: this evidence pack scored 10 candidate indications for canakinumab. Beyond FMF, only two others showed genuine (if preliminary) mechanistic and literature support; the remaining seven were flagged internally as likely database entity-mismatches with no real supporting evidence.

Disease	Evidence Level	Recommendation	Note
Periodic fever-infantile enterocolitis-autoinflammatory syndrome	L3	Research Question	19 publications, but concentrated on related-but-distinct CAPS/FMF/PFAPA syndromes rather than this specific entity
Blau syndrome	L3	Research Question	NOD2-driven granulomatous autoinflammation; small case series and a transcriptional-response cohort support IL-1β blockade, no controlled trials
Hepatic infarction, hepatic veno-occlusive disease, peliosis hepatis, extracutaneous mastocytoma, liver angiosarcoma	L5	Hold	No clinical trials; ≤1 unrelated literature hit each; judged as knowledge-graph association errors
Syndrome with combined immunodeficiency, monosomy X	L4–L5	Hold	Literature retrieved concerns unrelated drugs/diseases; disease-label mismatch

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: FMF has L1-grade evidence — five completed Phase 3 trials across the CAPS/TRAPS/FMF autoinflammatory disease family plus an ongoing real-world FMF-inclusive study, and 10+ dedicated FMF publications — and canakinumab already holds this indication in other major markets (FDA/EMA). However, the drug is currently unmarketed locally (0 authorizations), and two Blocking/High-severity data gaps prevent a full safety sign-off.

To proceed, the following is needed:

Local package insert (warnings, contraindications) — currently a Blocking data gap (DG001)
Formal DrugBank/MOA documentation for the local regulatory dossier — currently a High-severity data gap (DG002)
Completion of the local drug-drug interaction (DDI) query, currently returning "not found"
Confirmation of local filing/registration status and pathway for canakinumab given its current unmarketed status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.